BioXcel Therapeutics, Inc. Common Stock
Symbol: BTAI (NASDAQ)
6.13
▲ (29.05%) 1.380
Company Description:
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Key Stats
- Today's Open: $4.65
- Today's High: $6.595
- Today's Low: $4.17
- Today's Volume: 9.27M
- Yesterday Close: $4.75
- Yesterday High: $6.23
- Yesterday Low: $4.61
- Yesterday Volume: 8.33M
- Last Min Volume: 102
- Last Min High: $6.13
- Last Min Low: $6.115
- Last Min VWAP: $6.115
Company Profile
- Name: BioXcel Therapeutics, Inc. Common Stock
- Website: https://www.bioxceltherapeutics.com
- Listed Date: 2018-03-08
- Location: NEW HAVEN, CT
- Market Status: Active
- CIK Number: 0001720893
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $79.77M
- Round Lot: 100
- Outstanding Shares: 14.56M
- Asset Type: CS
RECENT FILINGS FOR BTAI
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-15 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-08-11 | 8-K | View |
| 2025-08-11 | 8-K | View |
| 2025-08-06 | 8-K | View |
| 2025-08-06 | 424B5 | View |
| 2025-08-05 | 4 | View |
| 2025-08-05 | 4 | View |
| 2025-08-05 | 4 | View |
| 2025-08-05 | 4 | View |
| 2025-08-01 | 8-K | View |
| 2025-07-31 | 4 | View |
| 2025-07-22 | 4 | View |
| 2025-07-22 | 4 | View |
| 2025-07-22 | 4 | View |
| 2025-07-22 | 4 | View |
| 2025-07-21 | 8-K | View |
| 2025-07-15 | 8-K | View |
| 2025-06-30 | 4 | View |
Latest News on BTAI